Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Símbolo de cotizaciónSLNO
Nombre de la empresaSoleno Therapeutics Inc
Fecha de salida a bolsaOct 23, 2014
Fundada en1999
Director ejecutivoDr. Anish Bhatnagar, M.D.
Número de empleados92
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 23
Dirección100 Marine Parkway, Suite 400
CiudadREDWOOD CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94065
Teléfono16502138444
Sitio Webhttps://soleno.life/
Símbolo de cotizaciónSLNO
Fecha de salida a bolsaOct 23, 2014
Fundada en1999
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos